December 2004
Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  
Nov   Jan


For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.


C H A N N E L S
• PULSE Home Page
• EXECUTIVE EDITION

• US News
• Canada News
• UK News
• New Zealand News

• Consumer Advocacy
• Health Care Systems
• Managed Care/Medicaid
• Co-occurring Disorders
• Clinical studies
• Pharmaceutical News
• Criminal Justice Systems
• Legislative News


U S E R ' S   G U I D E
About PULSE
PULSE Channels
Archives
Adding comments
Using the # link
Items that require registration
PULSE syndication
Tips for Searching PULSE


E M A I L   S U B S C R I P T I O N S

For WEEKLY summaries of PULSE postings, see the weekly email subscription form.

For DAILY mailings (powered by Bloglet), please enter your e-mail address below:


P U B L I C A T I O N S

PULSE ANNUAL No. 2
January 2003

Recent Trends, Challenges and Issues in Funding Public Mental Health Services in the US
March 2002

PULSE ANNUAL No. 1
October 2001

 

PULSE is powered by
Radio Userland.

Listed on BlogShares

© Bill Davis, 2000-2003.

About PULSE | Channels | User's Guide | Email subscriptions | Publications




PULSE is a free service of the Centre for Community Change International, gathering new and noteworthy Internet resources for mental health providers, family members of individuals with mental illness, consumers of mental health services and consumer advocates. PULSE is researched, edited and designed by Bill Davis.



daily link  Friday, December 17, 2004


Lilly Adds Warning to Strattera Label
Reuters story - "Eli Lilly and Co. on Friday said it added a warning to the label of its attention deficit/hyperactivity disorder medicine, advising patients with jaundice or a liver injury to stop taking the treatment. Lilly said the label change on the drug, known as Strattera, discusses two reported cases of severe liver injury out of the more than 2 million patients who have taken the medication since approval. Both patients have recovered with normal liver function after discontinuing the medication..."  
permalink